Friedelane-type oxidosqualene cyclases in friedelin production: Advances in biosynthesis, functional...

Friedelin, a unique friedelane-type pentacyclic triterpenoid, exhibits diverse pharmacological activities and serves as a key biosynthetic precursor for bioactive compounds such as anti-obesity agent celastrol. However, its structural complexity, arising from the extensive carbocation rearrangement cascade catalyzed by 2,3-oxidosqualene cyclases (OSCs), along with its low abundance in plants, poses significant challenges for sustainable production. Advances in multi-omics integration technologies have facilitated the identification and characterization of friedelane-type OSCs, with 18 such enzymes identified to date. Seminal structural studies, including the first cryogenic electron microscopy (cryo-EM) structure of a plant OSC, have elucidated the unique "cation shuttle-run" mechanism, providing valuable insights into the structure-function relationships governing catalytic specificity and efficiency. Concurrently, synthetic biology strategies have enabled the reconstruction of the friedelin biosynthetic pathway in engineered Saccharomyces cerevisiae. This review comprehensively synthesizes research progress, from the functional characterization and structure-function relationships of friedelane-type OSCs, to the development of integrated biotechnology strategies, including metabolic pathway engineering, protein engineering, and subcellular compartmentalization, which have enabled high-yield de novo production of friedelin. We also discuss future prospects for exploring OSC diversity and integrating systems biology, synthetic biology, and computational design to achieve sustainable biomanufacturing of friedelin and its high-value derivatives, while also addressing potential challenges in industrial applications.